Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut microbiota correlation with bevacizumab or PD-1 antibody efficacy in colorectal cancer
ChiCTR1900028063Phase 4Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab and PD-1 Monoclonal Antibody in colorectal cancer (CRC), sponsored by Shanghai Tenth People's Hospital. Primary endpoint: 16S sequencing. Started Dec 2019; status: recruiting.
02
Drugs
bevacizumabPD-1 Monoclonal Antibody
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1900028063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028063.